- $692.21m
- $460.10m
Immix Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Immix Biopharma Receives FDA RMAT Designation For NXC-201
Brief: Immix Biopharma Accelerates Enrollment In U.S. AL Amyloidosis Trial Of NXC-201 CAR-T
Brief: Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients In Nexicart-2 U.S. Trial
Immix Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary
Immix Biopharma Inc expected to post a loss of 16 cents a share - Earnings Preview
Immix Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Immix Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Renovorx Appoints Ryan Witt As Senior Vice President, Head Of Corporate Strategy And Partnerships
Immix Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Immix Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview
Immix Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Immix Biopharma Awarded European Union Orphan Drug Designation For Nxc-201 In Al Amyloidosis
Brief: Immix Biopharma Announces Pricing Of $15 Million Public Offering Of Common Stock
Brief: Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved Car-T Products
Brief: Immix Biopharma Announces 100% Overall Response Rate (N=10) 23.7 Months Best Response Duration (Ongoing) For Car-T Nxc-201 In Relapsed/Refractory Al Amyloidosis Patients At Ash 2023
U.S. STOCKS ON THE MOVE-Paramount Global, Bumble, Booking Holdings
Immix Biopharma jumps on positive trial data for protein disorder therapy
Brief: Immix Biopharma Completes 3rd NXC-201 Engineering Batch At Its U.S. CAR-T Manufacturing Site